4D Molecular Could Be 'Attractive Acquisition Target': BMO

 

• BMO Capital Markets initiated coverage on 4D Molecular Therapeutics Inc 
  FDMT
   with an Outperform rating and a price target of $50.
• The analyst writes that 4DMT's platform has generated competitive gene therapies and been clinically validated through its five ongoing clinical programs.
• BMO notes that 4D Molecular Therapeutics' Wet Age-Related Macular Degeneration (wet AMD) program addresses key limitations of approved/investigational therapies and can potentially confer a $5 billion
• The company's cystic Fibrosis asset 4D-710 can be the first therapy delivering clinical effects in patients without treatment options, potentially unlocking around $3 billion opportunity.
• In cystic fibrosis, a 3-5%+ improvement in FEV1 can drive FDMT stock over 50% higher and render the stock an attractive acquisition target. 
• Potential announcements around partnerships would trigger further upside.

https://www.benzinga.com/analyst-ratings/analyst-color/23/01/30626592/bmo-capital-markets-says-4d-molecular-could-be-attractive-acquisition-target